NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD. (NTproBNP)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Enrolling

Conditions: COPD

Study type: Observational

Funder types: Other

Identifiers

NCT06317428

INRCA_001_2024

Details and patient eligibility

About

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Full description

The purpose of the trixeo study is to conduct a prospective observational study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the initiation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Enrollment: 29 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COPD;
• Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide;

Exclusion criteria

• Life expectancy less than one year;